Develops polymer-based drug candidates and delivery technology for neurological diseases, including Parkinson’s disease, and potential RNA-based and antibody-linked therapies.
10-K for FY2025, filed Mar 25, 2026We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases…View ↗
Our business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for CNS indications, including…View ↗
We believe that our POZ platform delivery technology has potential for use across a broad range of payloads and indications. Among our…View ↗
Receives government grants that reimburse certain eligible project costs, with payments tied to research and development costs incurred for the funded projects.
10-K for FY2025, filed Mar 25, 2026The Company receives government grants that reimburse the Company for certain allowable costs for funded projects. Grant revenue is…View ↗
$130K
10-K for FY2025, filed Mar 25, 2026
$130K ↗No. It lost $19.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$7.9MView ↗
8-K, filed Sep 9, 2026
On September 9, 2026, the Company issued a press release announcing that the Independent Safety Monitoring Committee has completed its…View ↗
Shrinking. Revenue fell 10% in 4 years, from $144K in FY2021 to $130K in FY2025, about 3% a year.
From regenerative medicine to drug delivery
The older report described cell therapies and regenerative technologies for aging-related diseases. The newer report centers on POZ-enabled drug candidates for neurological diseases and other indications.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 25, 2026We are a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and…View ↗
Our proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows us to utilize…View ↗
Our product candidates in the discovery stage include two cell-based therapies derived from telomerase-positive PSCs and two product…View ↗
Loading...